IP Library Granted Patent US 12,606,814
Granted Patent B2
US 12,606,814 · App. 17/680,983 · Granted Apr 21, 2026

Oligonucleotide probes and uses thereof

Inventors: Valeriy Domenyuk (Phoenix, AZ); Tassilo Hornung (Phoenix, AZ); Mark Miglarese (Phoenix, AZ); David Spetzler (Paradise Valley, AZ)
Assignee: Caris Science, Inc.
C12N15/1006C12N15/115C40B20/02C40B20/04C40B40/08C12N2310/16C12N2320/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,606,814
App. No.
17/680,983
Granted
Apr 21, 2026
Kind
B2
Abstract

Methods and compositions are provided to identify oligonucleotides that bind targets of interest. The targets include tissues, cells, circulating biomarkers such as microvesicles, including those derived from various diseases. The oligonucleotides can be used in diagnostic and therapeutic applications.

Claims (27)

1 . A method of enriching an oligonucleotide probe library comprising a plurality of oligonucleotides, the method comprising:

(a) providing a planar support arrayed with a plurality of samples, wherein a portion of the plurality of samples differs from another portion of the plurality of samples according to a phenotype of interest;

(b) contacting the plurality of samples arrayed on the planar support with the plurality of oligonucleotides; and

(c) recovering members of the oligonucleotide probe library that bound to members of the portion of samples of one phenotype of interest, thereby enriching the oligonucleotide probe library.

2 . The method of claim 1 , further comprising repeating steps (a)-(c) at least 5 times.

3 . The method of claim 1 , wherein the unenriched oligonucleotide probe library comprises at least 106 different oligonucleotide sequences.

4 . The method of claim 1 , wherein the plurality of samples comprises a cell culture, a tissue sample, a tissue lysate, a bodily fluid or a fraction, derivative or combination thereof.

5 . The method of claim 4 , wherein the bodily fluid comprises at least one of blood or a derivative thereof, sera, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, bronchoalveolar lavage fluid, semen, prostatic fluid, Cowper's fluid, pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair oil, tears, cyst fluid, pleural fluid, peritoneal fluid, malignant fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, and other lavage fluids.

6 . The method of claim 4 , wherein each of the plurality of samples comprises microvesicles.

7 . The method of claim 6 , further comprising isolating the microvesicles prior to step (a).

8 . The method of claim 7 , wherein isolating the microvesicles comprises at least one of filtration, ultracentrifugation, affinity isolation, size exclusion chromatography and polymer precipitation.

9 . The method of claim 8 , wherein the polymer comprises polyethylene glycol (PEG).

10 . The method of claim 1 , wherein the planar support comprises a well, a glass slide or a membrane.

11 . The method of claim 10 , wherein the membrane comprises a polymer membrane or a nitrocellulose membrane.

12 . The method of claim 11 , wherein the phenotype is a tissue, an anatomical origin, a medical condition, a disease or a disorder.

13 . The method of claim 12 , wherein the phenotype is a cancer sample, a non-cancer sample, a sample from a responder to a treatment, or a sample from a non-responder to a treatment.

14 . The method of claim 1 , wherein members of the portions of different phenotypes of interest are from different sections of a same substrate, and some or all members of the portions of different phenotypes of interest are scraped or microdissected from the same substrate.

15 . A method of characterizing a phenotype of interest in a sample comprising:

(a) enriching a plurality of oligonucleotides to characterize the phenotype of interest according to the method of claim 1 ;

(b) arraying at least one sample on a substrate;

(c) contacting the substrate with the plurality of oligonucleotides enriched in step (a); and

(d) measuring a presence or level of a complex formed between members of the plurality of oligonucleotides and the samples arrayed on the substrate, wherein the presence or level is used to characterize the phenotype of interest.

16 . The method of claim 15 , wherein the sample comprises microvesicles isolated from a bodily fluid.

17 . The method of claim 16 , wherein the bodily fluid comprises peripheral blood, sera, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, bronchoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair oil, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocoel cavity fluid, or umbilical cord blood.

18 . The method of claim 15 , wherein the measuring comprises sequencing, amplification, hybridization, gel electrophoresis, chromatography, or visualization.

19 . The method of claim 18 , wherein the hybridization comprises contacting the sample with at least one labeled probe that is configured to hybridize with members of the plurality of oligonucleotides.

20 . The method of claim 18 , wherein the visualization comprises visualizing a signal linked directly or indirectly to members of the plurality of oligonucleotides.

Assignments (4)
RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME NO. 62419/0390 Recorded Apr 1, 2026
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: CARIS MPI, INC.; CARIS SCIENCE, INC.
Reel/Frame 075424/0290 →
PATENT SECURITY AGREEMENT Recorded Apr 1, 2026
From: CARIS SCIENCE, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 075362/0668 →
SECURITY INTEREST Recorded Jan 18, 2023
From: CARIS MPI, INC.; CARIS SCIENCE, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 062419/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2022
From: DOMENYUK, VALERIY; HORNUNG, TASSILO; MIGLARESE, MARK; SPETZLER, DAVID
To: CARIS SCIENCE, INC.
Reel/Frame 059112/0813 →
Continuity (10)
Continuation 16304389
Provisional Application 62508353 · May 18, 2017
Provisional Application 62472953 · Mar 17, 2017
Provisional Application 62457691 · Feb 10, 2017
Provisional Application 62441527 · Jan 2, 2017
Provisional Application 62432561 · Dec 9, 2016
Provisional Application 62420497 · Nov 10, 2016
Provisional Application 62413361 · Oct 26, 2016
Provisional Application 62341617 · May 25, 2016
Related Publication 20220290124A1 · Sep 15, 2022
References Cited (400)
US 3687808A · Merigan et al. · 1972 [cited by applicant]
US 4016043A · Schuurs et al. · 1977 [cited by applicant]
US 4018653A · Mennen · 1977 [cited by applicant]
US 4275149A · Litman et al. · 1981 [cited by applicant]
US 4376110A · David et al. · 1983 [cited by applicant]
US 4424279A · Bohn et al. · 1984 [cited by applicant]
US 4469863A · Ts'o et al. · 1984 [cited by applicant]
US 4476301A · Imbach et al. · 1984 [cited by applicant]
US 4486530A · David et al. · 1984 [cited by applicant]
US 4551435A · Liberti et al. · 1985 [cited by applicant]
US 4587044A · Miller et al. · 1986 [cited by applicant]
US 4605735A · Miyoshi et al. · 1986 [cited by applicant]
US 4667025A · Miyoshi et al. · 1987 [cited by applicant]
US 4737456A · Weng et al. · 1988 [cited by applicant]
US 4762779A · Snitman et al. · 1988 [cited by applicant]
US 4789737A · Miyoshi et al. · 1988 [cited by applicant]
US 4795698A · Owen et al. · 1989 [cited by applicant]
US 4824941A · Gordon et al. · 1989 [cited by applicant]
US 4828979A · Klevan et al. · 1989 [cited by applicant]
US 4835263A · Nguyen et al. · 1989 [cited by applicant]
US 4845205A · Dinh et al. · 1989 [cited by applicant]
US 4876335A · Yamane et al. · 1989 [cited by applicant]
US 4904582A · Tullis · 1990 [cited by applicant]
US 4925788A · Liberti · 1990 [cited by applicant]
US 4948882A · Ruth · 1990 [cited by applicant]
US 4958013A · Letsinger · 1990 [cited by applicant]
US 5013830A · Ohtsuka et al. · 1991 [cited by applicant]
US 5023243A · Tullis · 1991 [cited by applicant]
US 5034506A · Summerton et al. · 1991 [cited by applicant]
US 5082830A · Brakel et al. · 1992 [cited by applicant]
US 5108933A · Liberti et al. · 1992 [cited by applicant]
US 5109124A · Ramachandran et al. · 1992 [cited by applicant]
US 5112963A · Pieles et al. · 1992 [cited by applicant]
US 5118802A · Smith et al. · 1992 [cited by applicant]
US 5130302A · Spielvogel et al. · 1992 [cited by applicant]
US 5134066A · Rogers et al. · 1992 [cited by applicant]
US 5138045A · Cook et al. · 1992 [cited by applicant]
US 5149797A · Pederson et al. · 1992 [cited by applicant]
US 5158871A · Rossomando et al. · 1992 [cited by applicant]
US 5166315A · Summerton et al. · 1992 [cited by applicant]
US 5175273A · Bischofberger et al. · 1992 [cited by applicant]
US 5177196A · Meyer, Jr. et al. · 1993 [cited by applicant]
US 5185444A · Summerton et al. · 1993 [cited by applicant]
US 5186827A · Liberti et al. · 1993 [cited by applicant]
US 5188897A · Suhadolnik et al. · 1993 [cited by applicant]
US 5200084A · Liberti et al. · 1993 [cited by applicant]
US 5214134A · Weis et al. · 1993 [cited by applicant]
US 5214136A · Lin et al. · 1993 [cited by applicant]
US 5216141A · Benner · 1993 [cited by applicant]
US 5218105A · Cook et al. · 1993 [cited by applicant]
US 5220007A · Pederson et al. · 1993 [cited by applicant]
US 5235033A · Summerton et al. · 1993 [cited by applicant]
US 5245022A · Weis et al. · 1993 [cited by applicant]
US 5254469A · Warren, III et al. · 1993 [cited by applicant]
US 5256775A · Froehler · 1993 [cited by applicant]
US 5258506A · Urdea et al. · 1993 [cited by applicant]
US 5262536A · Hobbs, Jr. · 1993 [cited by applicant]
US 5264423A · Cohen et al. · 1993 [cited by applicant]
US 5264562A · Matteucci · 1993 [cited by applicant]
US 5264564A · Matteucci · 1993 [cited by applicant]
US 5270163A · Gold et al. · 1993 [cited by applicant]
US 5272250A · Spielvogel et al. · 1993 [cited by applicant]
US 5276019A · Cohen et al. · 1994 [cited by applicant]
US 5278302A · Caruthers et al. · 1994 [cited by applicant]
US 5286717A · Cohen et al. · 1994 [cited by applicant]
US 5292873A · Rokita et al. · 1994 [cited by applicant]
US 5317098A · Shizuya et al. · 1994 [cited by applicant]
US 5321131A · Agrawal et al. · 1994 [cited by applicant]
US 5366878A · Pederson et al. · 1994 [cited by applicant]
US 5367066A · Urdea et al. · 1994 [cited by applicant]
US 5371241A · Brush · 1994 [cited by applicant]
US 5376252A · Eksrom et al. · 1994 [cited by applicant]
US 5391723A · Priest · 1995 [cited by applicant]
US 5399676A · Froehler · 1995 [cited by applicant]
US 5403711A · Walder et al. · 1995 [cited by applicant]
US 5405938A · Summerton et al. · 1995 [cited by applicant]
US 5405939A · Suhadolnik et al. · 1995 [cited by applicant]
US 5414077A · Lin et al. · 1995 [cited by applicant]
US 5416203A · Letsinger · 1995 [cited by applicant]
US 5432272A · Benner · 1995 [cited by applicant]
US 5434257A · Matteucci · 1995 [cited by applicant]
US 5451463A · Nelson et al. · 1995 [cited by applicant]
US 5453496A · Caruthers et al. · 1995 [cited by applicant]
US 5455233A · Spielvogel et al. · 1995 [cited by applicant]
US 5457187A · Gmeiner et al. · 1995 [cited by applicant]
US 5459255A · Cook et al. · 1995 [cited by applicant]
US 5466677A · Baxter et al. · 1995 [cited by applicant]
US 5470967A · Huie et al. · 1995 [cited by applicant]
US 5475096A · Gold et al. · 1995 [cited by applicant]
US 5476925A · Letsinger et al. · 1995 [cited by applicant]
US 5484908A · Froehler et al. · 1996 [cited by applicant]
US 5486603A · Buhr · 1996 [cited by applicant]
US 5489677A · Sanghvi et al. · 1996 [cited by applicant]
US 5491133A · Walder et al. · 1996 [cited by applicant]
US 5496938A · Gold et al. · 1996 [cited by applicant]
US 5502177A · Matteucci et al. · 1996 [cited by applicant]
US 5510475A · Agrawal et al. · 1996 [cited by applicant]
US 5512439A · Hornes et al. · 1996 [cited by applicant]
US 5512667A · Reed et al. · 1996 [cited by applicant]
US 5514785A · Van Ness et al. · 1996 [cited by applicant]
US 5519126A · Hecht · 1996 [cited by applicant]
US 5525465A · Haralambidis et al. · 1996 [cited by applicant]
US 5525711A · Hawkins et al. · 1996 [cited by applicant]
US 5536821A · Agrawal et al. · 1996 [cited by applicant]
US 5539082A · Nielsen et al. · 1996 [cited by applicant]
US 5541306A · Agrawal et al. · 1996 [cited by applicant]
US 5541307A · Cook et al. · 1996 [cited by applicant]
US 5541313A · Ruth · 1996 [cited by applicant]
US 5545730A · Urdea et al. · 1996 [cited by applicant]
US 5550111A · Suhadolnik et al. · 1996 [cited by applicant]
US 5552538A · Urdea et al. · 1996 [cited by applicant]
US 5552540A · Haralambidis · 1996 [cited by applicant]
US 5561225A · Maddry et al. · 1996 [cited by applicant]
US 5563253A · Agrawal et al. · 1996 [cited by applicant]
US 5565350A · Kmiec · 1996 [cited by applicant]
US 5565552A · Magda et al. · 1996 [cited by applicant]
US 5567588A · Gold et al. · 1996 [cited by applicant]
US 5567810A · Weis et al. · 1996 [cited by applicant]
US 5571799A · Tkachuk et al. · 1996 [cited by applicant]
US 5574142A · Meyer, Jr. et al. · 1996 [cited by applicant]
US 5578717A · Urdea et al. · 1996 [cited by applicant]
US 5578718A · Cook et al. · 1996 [cited by applicant]
US 5580731A · Chang et al. · 1996 [cited by applicant]
US 5580737A · Polinsky et al. · 1996 [cited by applicant]
US 5585481A · Arnold, Jr. et al. · 1996 [cited by applicant]
US 5587361A · Cook et al. · 1996 [cited by applicant]
US 5587371A · Sessler et al. · 1996 [cited by applicant]
US 5587469A · Cook et al. · 1996 [cited by applicant]
US 5591584A · Chang et al. · 1997 [cited by applicant]
US 5595726A · Magda et al. · 1997 [cited by applicant]
US 5596086A · Matteucci et al. · 1997 [cited by applicant]
US 5596091A · Switzer · 1997 [cited by applicant]
US 5597696A · Linn et al. · 1997 [cited by applicant]
US 5599923A · Sessler et al. · 1997 [cited by applicant]
US 5599928A · Hemmi et al. · 1997 [cited by applicant]
US 5602240A · Mesmaeker et al. · 1997 [cited by applicant]
US 5608046A · Cook et al. · 1997 [cited by applicant]
US 5610289A · Cook et al. · 1997 [cited by applicant]
US 5614617A · Cook et al. · 1997 [cited by applicant]
US 5618704A · Sanghvi et al. · 1997 [cited by applicant]
US 5623065A · Cook et al. · 1997 [cited by applicant]
US 5623070A · Cook et al. · 1997 [cited by applicant]
US 5625050A · Beaton et al. · 1997 [cited by applicant]
US 5633360A · Bischofberger et al. · 1997 [cited by applicant]
US 5637459A · Burke et al. · 1997 [cited by applicant]
US 5648214A · Nieuwlandt et al. · 1997 [cited by applicant]
US 5652355A · Metelev et al. · 1997 [cited by applicant]
US 5652356A · Agrawal et al. · 1997 [cited by applicant]
US 5660985A · Pieken et al. · 1997 [cited by applicant]
US 5663312A · Chaturvedula et al. · 1997 [cited by applicant]
US 5672695A · Eckstein et al. · 1997 [cited by applicant]
US 5677437A · Teng et al. · 1997 [cited by applicant]
US 5677439A · Weis et al. · 1997 [cited by applicant]
US 5681941A · Cook et al. · 1997 [cited by applicant]
US 5683867A · Biesecker et al. · 1997 [cited by applicant]
US 5688941A · Cook et al. · 1997 [cited by applicant]
US 5698687A · Eckstein et al. · 1997 [cited by applicant]
US 5700922A · Cook · 1997 [cited by applicant]
US 5705337A · Gold et al. · 1998 [cited by applicant]
US 5707796A · Gold et al. · 1998 [cited by applicant]
US 5714331A · Buchardt et al. · 1998 [cited by applicant]
US 5719262A · Buchardt et al. · 1998 [cited by applicant]
US 5736330A · Fulton · 1998 [cited by applicant]
US 5750692A · Cook et al. · 1998 [cited by applicant]
US 5763177A · Gold et al. · 1998 [cited by applicant]
US 5817635A · Eckstein et al. · 1998 [cited by applicant]
US 5858731A · Sorge et al. · 1999 [cited by applicant]
US 5861254A · Schneider et al. · 1999 [cited by applicant]
US 5958691A · Pieken et al. · 1999 [cited by applicant]
US 6011020A · Gold et al. · 2000 [cited by applicant]
US 6051698A · Janjic et al. · 2000 [cited by applicant]
US 6057107A · Fulton · 2000 [cited by applicant]
US 6329209B1 · Wagner et al. · 2001 [cited by applicant]
US 6365418B1 · Wagner et al. · 2002 [cited by applicant]
US 6406921B1 · Wagner et al. · 2002 [cited by applicant]
US 6408878B2 · Unger et al. · 2002 [cited by applicant]
US 6475808B1 · Wagner et al. · 2002 [cited by applicant]
US 6475809B1 · Wagner et al. · 2002 [cited by applicant]
US 6599331B2 · Chandler et al. · 2003 [cited by applicant]
US 6623526B1 · Lloyd · 2003 [cited by applicant]
US 6645432B1 · Anderson et al. · 2003 [cited by applicant]
US 6719868B1 · Schueller et al. · 2004 [cited by applicant]
US 6773812B2 · Chandler et al. · 2004 [cited by applicant]
US 6793753B2 · Unger et al. · 2004 [cited by applicant]
US 6899137B2 · Unger et al. · 2005 [cited by applicant]
US 6929030B2 · Unger et al. · 2005 [cited by applicant]
US 7040338B2 · Unger et al. · 2006 [cited by applicant]
US 7118661B2 · Surh et al. · 2006 [cited by applicant]
US 7118910B2 · Unger et al. · 2006 [cited by applicant]
US 7125711B2 · Pugia et al. · 2006 [cited by applicant]
US 7135147B2 · Cox et al. · 2006 [cited by applicant]
US 7138062B2 · Yin et al. · 2006 [cited by applicant]
US 7141978B2 · Peck et al. · 2006 [cited by applicant]
US 7144616B1 · Unger et al. · 2006 [cited by applicant]
US 7189368B2 · Andersson et al. · 2007 [cited by applicant]
US 7189580B2 · Beebe et al. · 2007 [cited by applicant]
US 7189581B2 · Beebe et al. · 2007 [cited by applicant]
US 7195986B1 · Bousse et al. · 2007 [cited by applicant]
US 7201881B2 · Cox et al. · 2007 [cited by applicant]
US 7216671B2 · Unger et al. · 2007 [cited by applicant]
US 7229538B2 · Tseng et al. · 2007 [cited by applicant]
US 7233865B2 · Chien · 2007 [cited by applicant]
US 7238255B2 · Derand et al. · 2007 [cited by applicant]
US 7238324B2 · Ko et al. · 2007 [cited by applicant]
US 7250128B2 · Unger et al. · 2007 [cited by applicant]
US 7253003B2 · Beebe et al. · 2007 [cited by applicant]
US 7258837B2 · Yager et al. · 2007 [cited by applicant]
US 7261824B2 · Schlautmann et al. · 2007 [cited by applicant]
US 7274316B2 · Moore · 2007 [cited by applicant]
US 7323140B2 · Handique et al. · 2008 [cited by applicant]
US 7329391B2 · Cox · 2008 [cited by applicant]
US 7338637B2 · Pease et al. · 2008 [cited by applicant]
US 7351380B2 · Simmons et al. · 2008 [cited by applicant]
US 7351592B2 · Storek et al. · 2008 [cited by applicant]
US 7357864B2 · Takada et al. · 2008 [cited by applicant]
US 7381471B2 · Augustine et al. · 2008 [cited by applicant]
US 7390463B2 · He et al. · 2008 [cited by applicant]
US 7399600B2 · Carr · 2008 [cited by applicant]
US 7399632B2 · Simmons et al. · 2008 [cited by applicant]
US 7402229B2 · Sibbett et al. · 2008 [cited by applicant]
US 7411184B2 · Sarrut · 2008 [cited by applicant]
US 7413709B2 · Roitman et al. · 2008 [cited by applicant]
US 7419639B2 · Osterfeld et al. · 2008 [cited by applicant]
US 7419822B2 · Jeon et al. · 2008 [cited by applicant]
US 7422669B2 · Jacobson et al. · 2008 [cited by applicant]
US 7422725B2 · Kimizuka · 2008 [cited by applicant]
US 7431887B2 · Storek et al. · 2008 [cited by applicant]
US 7445844B2 · Chandler et al. · 2008 [cited by applicant]
US 7449096B2 · Berndt et al. · 2008 [cited by applicant]
US 7452509B2 · Cox et al. · 2008 [cited by applicant]
US 7452713B2 · Barlocchi et al. · 2008 [cited by applicant]
US 7467928B2 · Fakunle et al. · 2008 [cited by applicant]
US 7485214B2 · Palmieri · 2009 [cited by applicant]
US 7488596B2 · Palmieri · 2009 [cited by applicant]
US 7494555B2 · Unger et al. · 2009 [cited by applicant]
US 7501245B2 · Quake et al. · 2009 [cited by applicant]
US 7518726B2 · Rulison et al. · 2009 [cited by applicant]
US 7541578B2 · Weng · 2009 [cited by applicant]
US 7544506B2 · Breidford et al. · 2009 [cited by applicant]
US 7552741B2 · Yamada et al. · 2009 [cited by applicant]
US 7568399B2 · Sparks et al. · 2009 [cited by applicant]
US 7575722B2 · Arnold · 2009 [cited by applicant]
US 7579136B2 · Shim et al. · 2009 [cited by applicant]
US 7581429B2 · Sparks et al. · 2009 [cited by applicant]
US 7591936B2 · Sarrut · 2009 [cited by applicant]
US 7601270B1 · Unger et al. · 2009 [cited by applicant]
US 7640947B2 · Fernandes et al. · 2010 [cited by applicant]
US 7666361B2 · McBride et al. · 2010 [cited by applicant]
US 7691333B2 · McBride et al. · 2010 [cited by applicant]
US 7704735B2 · Facer et al. · 2010 [cited by applicant]
US 7751053B2 · Carr · 2010 [cited by applicant]
US 7754010B2 · Unger et al. · 2010 [cited by applicant]
US 7837946B2 · McBride et al. · 2010 [cited by applicant]
US 7955802B2 · Whitman et al. · 2011 [cited by applicant]
US 8008019B2 · Merante et al. · 2011 [cited by applicant]
US 8124015B2 · Diercks et al. · 2012 [cited by applicant]
US 10731166B2 · Domenyuk et al. · 2020 [cited by applicant]
US 11332748B2 · Domenyuk et al. · 2022 [cited by applicant]
US 20030061687A1 · Hansen et al. · 2003 [cited by applicant]
US 20050084421A1 · Unger et al. · 2005 [cited by applicant]
US 20050112882A1 · Unger et al. · 2005 [cited by applicant]
US 20050129581A1 · McBride et al. · 2005 [cited by applicant]
US 20050145496A1 · Goodsaid et al. · 2005 [cited by applicant]
US 20050201901A1 · Grossman et al. · 2005 [cited by applicant]
US 20050214173A1 · Facer et al. · 2005 [cited by applicant]
US 20050252773A1 · McBride et al. · 2005 [cited by applicant]
US 20060006067A1 · Unger · 2006 [cited by applicant]
US 20060257900A1 · Hudson et al. · 2006 [cited by applicant]
US 20090264508A1 · Sullenger et al. · 2009 [cited by applicant]
US 20120258870A1 · Schwartz et al. · 2012 [cited by applicant]
US 20120328607A1 · Hicks et al. · 2012 [cited by applicant]
US 20130017837A1 · Hakola et al. · 2013 [cited by applicant]
US 20130065778A1 · Weidhaas · 2013 [cited by applicant]
US 20130217582A1 · Borer et al. · 2013 [cited by applicant]
US 20140094383A1 · Lee et al. · 2014 [cited by applicant]
US 20140371088A1 · Webster · 2014 [cited by applicant]
US 20190078093A1 · Domenyuk et al. · 2019 [cited by applicant]
US 20210062191A1 · Domenyuk et al. · 2021 [cited by applicant]
CN 104498500 · 2015 [cited by applicant]
EP 0527905 · 1993 [cited by applicant]
EP 1065378 · 2001 [cited by applicant]
EP 2703488 · 2014 [cited by applicant]
JP 2008535482 · 2008 [cited by applicant]
WO WO199119813 · 1991 [cited by applicant]
WO WO199207065 · 1992 [cited by applicant]
WO WO1993022684 · 1993 [cited by applicant]
WO WO199818480 · 1998 [cited by applicant]
WO WO2007137187 · 2007 [cited by applicant]
WO WO2009015357 · 2009 [cited by applicant]
WO WO2009036236 · 2009 [cited by applicant]
WO WO2010045318 · 2010 [cited by applicant]
WO WO2010056337 · 2010 [cited by applicant]
WO WO2010062706 · 2010 [cited by applicant]
WO WO2010072410 · 2010 [cited by applicant]
WO WO2010093465 · 2010 [cited by applicant]
WO WO2011056688 · 2011 [cited by applicant]
WO WO2011066589 · 2011 [cited by applicant]
WO WO2011088226 · 2011 [cited by applicant]
WO WO2011109440 · 2011 [cited by applicant]
WO WO2011127219 · 2011 [cited by applicant]
WO WO2012024543 · 2012 [cited by applicant]
WO WO2012092336 · 2012 [cited by applicant]
WO WO2012115885 · 2012 [cited by applicant]
WO WO2012147800 · 2012 [cited by applicant]
WO WO2012170711 · 2012 [cited by applicant]
WO WO2012170715 · 2012 [cited by applicant]
WO WO2012174282 · 2012 [cited by applicant]
WO WO2013022995 · 2013 [cited by applicant]
WO WO2013134786 · 2013 [cited by applicant]
WO WO2013022786 · 2014 [cited by applicant]
WO WO2014068408 · 2014 [cited by applicant]
WO WO2014082083 · 2014 [cited by applicant]
WO WO2014089241 · 2014 [cited by applicant]
WO WO2014100434 · 2014 [cited by applicant]
WO WO2015031694 · 2015 [cited by applicant]
WO WO2015116868 · 2015 [cited by applicant]
WO WO2015164238 · 2015 [cited by applicant]
WO WO2016018934 · 2016 [cited by applicant]
WO WO2016081941 · 2016 [cited by applicant]
WO WO2016141169 · 2016 [cited by applicant]
WO WO2016145128 · 2016 [cited by applicant]
WO WO2017004243 · 2017 [cited by applicant]
WO WO2017019918 · 2017 [cited by applicant]
WO WO2017205686 · 2017 [cited by applicant]
AU Examination Report in Australian Appln. No 2017271579, dated Sep. 30, 2022, 3 pages. [cited by applicant]
US 5,756,703, Apr. 5, 1982, (withdrawn). [cited by applicant]
U.S. Appl. No. 07/536,428, filed Jun. 11, 1990, Gold, et al. [cited by applicant]
U.S. Appl. No. 10/729,581, filed Dec. 3, 2003, Keefe, et al. [cited by applicant]
U.S. Appl. No. 10/873,856, filed Jun. 21, 2004, Keefe, et al. [cited by applicant]
U.S. Appl. No. 16/304,389, filed Nov. 26, 2018, Domenyuk et al. [cited by applicant]
U.S. Appl. No. 60/430,761, filed Dec. 3, 2002, Keefe, et al. [cited by applicant]
U.S. Appl. No. 60/487,474, filed Jul. 15, 2003, Keefe, et al. [cited by applicant]
U.S. Appl. No. 60/517,039, filed Nov. 4, 2003, Keefe, et al. [cited by applicant]
U.S. Appl. No. 62/310,665, filed Mar. 18, 2016, Domenyuk, et al. [cited by applicant]
U.S. Appl. No. 62/341,617, filed May 25, 2016, Domenyuk, et al. [cited by applicant]
U.S. Appl. No. 62/413,361, filed Oct. 26, 2016, Domenyuk, et al. [cited by applicant]
U.S. Appl. No. 62/420,497, filed Nov. 10, 2016, Domenyuk, et al. [cited by applicant]
U.S. Appl. No. 62/432,561, filed Dec. 9, 2016, Domenyuk, et al. [cited by applicant]
U.S. Appl. No. 62/441,527, filed Jan. 2, 2017, Domenyuk, et al. [cited by applicant]
U.S. Appl. No. 62/457,691, filed Feb. 10, 2017, Hornung, et al. [cited by applicant]
U.S. Appl. No. 62/472,953, filed Mar. 17, 2017, Hornung, et al. [cited by applicant]
U.S. Appl. No. 62/508,353, filed May 18, 2017, Domenyuk, et al. [cited by applicant]
[No Author Listed] “Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics,” Washington, DC, US Food and Drug Administration, May 2007, 19 pages. [cited by applicant]
Altschul et al., “Basic local alignment search tool,” Journal of molecular biology, Oct. 5, 1990, 215(3):403-10. [cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Research Sep. 1, 1997, 25(17):3389-402. [cited by applicant]
Avci-Adali et al., “Upgrading SELEX technology by using lambda exonuclease digestion for single-stranded DNA generation,” Molecules, Jan. 2010, 15(1): 11 Pages. [cited by applicant]
Bartsch et al., “Trastuzumab in the management of early and advanced stage breast cancer,” Biologics: Targets & Therapy, Mar. 2007, 1(1):19-31. [cited by applicant]
Bonotto et al., “Treatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines?,” The Oncologist, Jul. 1, 2015, 20(7):719-… [cited by applicant]
Braasch et al., “Novel antisense and peptide nucleic acid strategies for controlling gene expression,” Biochemistry, Apr. 9, 2002, 41(14):4503-10. [cited by applicant]
Brody et al., “Aptamers as therapeutic and diagnostic agents,” Reviews in Molecular Biotechnology, Mar. 1, 2000, 74(1):5-13. [cited by applicant]
Budayeva et al., “A mass spectrometry view of stable and transient protein interactions,” Advancements of Mass Spectrometry in Biomedical Research, Springer, Cham, 2014, 263-282. [cited by applicant]
Burstein, “The distinctive nature of HER2-positive breast cancers,” New England Journal of Medicine, Oct. 20, 2005, 353(16):1652-4. [cited by applicant]
Chang et al., “Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells,” Cell Death & Disease, Nov. 5, 2014, (11):e1540, 12 pages. [cited by applicant]
Charras et al., “Blebs lead the way: how to migrate without lamellipodia,” Nature Reviews Molecular Cell Biology, Sep. 2008, 9(9):730-6. [cited by applicant]
Chen et al., “Aptamer microarray as a novel bioassay for protein-protein interaction discovery and analysis,” Biosensors and Bioelectronics, Apr. 15, 2013, 42:248-55. [cited by applicant]
Chen et al., “Microfluidic isolation and transcriptome analysis of serum microvesicles,” Lab on a Chip, 2010, 10(4):505-11. [cited by applicant]
ClinicalTrials.gov, “Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,” Jan. 12, 2011, retreived from URL <https://clinicaltrials.gov/ct2/show/NCT01275677?term=NSABP+B… [cited by applicant]
Colcher et al., “Effects of genetic engineering on the pharmacokinetics of antibodies,” The Quarterly Journal of Nuclear Medicine and Molecular Imaging. Jun. 1, 1999;43(2):132-9. [cited by applicant]
Cotten et al., “ 2′-O-methyl, 2′-O-ethyl oligoribonucleotides and phosphorothioate oligodeoxyribonucleotides as inhibitors of the in vitro U7 snRNP-dependent mRNA processing event,” Nucleic Acids Research, May 25, 1991,… [cited by applicant]
Crooke et al., “Pharmacokinetic properties of several novel oligonucleotide analogs in mice,” Journal of Pharmacology and Experimental Therapeutics, May 1, 1996, 277(2):923-37. [cited by applicant]
Cutillas et al., “Proteomic analysis of plasma membrane vesicles isolated from the rat renal cortex,” Proteomics, Jan. 2005, 5(1):101-12. [cited by applicant]
Cutillas et al., “Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line,” Molecular & Ce… [cited by applicant]
De Mesmaeker et al., “Antisense oligonucleotides,” Accounts of Chemical Research, Sep. 1, 1995, 28(9):366-74. [cited by applicant]
DNA Replication, 2nd Ed., 1980, Chapter 2, 47 pages. [cited by applicant]
Domenyuk et al., “Plasma exosome profiling of cancer patients by a next generation systems biology approach,” Scientific Reports, Feb. 20, 2017, 7:42741. [cited by applicant]
Duffy et al., “Companion biomarkers: paving the pathway to personalized treatment for cancer,” Clinical Chemistry, Oct. 1, 2013, 59(10):1447-56. [cited by applicant]
EP extended European Search Report in EP Appln. No. 17803629.9, dated Feb. 14, 2020, 10 Pages. [cited by applicant]
EP Office Action in European Appln. No. 17803629.9, dated Jan. 12, 2021, 6 pages. [cited by applicant]
EP Search Report in International Appln. 17767690.5, dated Oct. 9, 2019, 41 Pages. [cited by applicant]
Epelbaum et al., Molecular profiling-selected therapy for treatment of advanced pancreaticobiliary cancer: a retrospective multicenter study, BioMed Research International, 2015, 2015, 9 pages. [cited by applicant]
Espelund et al., “A simple method for generating single-stranded DNA probes labeled to high activities,” Nucleic Acids Research, Oct. 25, 1990, 18(20):6157-8. [cited by applicant]
Eswarakumar et al., “Cellular signaling by fibroblast growth factor receptors,” Cytokine & Growth Factor Reviews, Apr. 1, 2005, 16(2):139-49. [cited by applicant]
Famulok et al., “Aptamer modules as sensors and detectors,” Accounts of Chemical Research, Aug. 5, 2011, 44(12):1349-58. [cited by applicant]
Famulok et al., “Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy,” Chemical Reviews, Sep. 12, 2007, 107(9):3715-43. [cited by applicant]
Faoro et al., “Ribonomic approaches to study the RNA-binding proteome,” FEBS Letters, Oct. 16, 2014. 588(20):3649-64. [cited by applicant]
Fouz et al., “Gene expression analysis in MCF-7 breast cancer cells treated with recombinant bromelain,” Applied Biochemistry and Biotechnology, Aug. 1, 2014, 173(7):1618-39. [cited by applicant]
Froehler et al., “Synthesis of DNA via deoxynudeoside H-phosphonate intermediates,” Nucleic Acids Research, Jul. 11, 1986, 5399-407. [cited by applicant]
Froehler, “Deoxynucleoside H-phosphonate diester intermediates in the synthesis of internucleotide phosphate analogues,” Tetrahedron Letters, Jan. 1, 1986, 27(46):5575-8. [cited by applicant]
Garraway et al., “Lessons from the cancer genome,” Cell, Mar. 28, 2013, 153(1):17-37. [cited by applicant]
Gatalica et al., “The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma,” Cancer, Mar. 15, 2000, 88(6):1378-83. [cited by applicant]
Gerlinger et al., “Intratumor heterogeneity and branched evolution revealed by multiregion sequencing,” New England Journal of Medicine, Mar. 8, 2012, 366(10):883-92. [cited by applicant]
Gyllensten et al., “Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus,” Proceedings of the National Academy of Sciences, Oct. 1, 1988,85(20)… [cited by applicant]
Hanahan et al., “Hallmarks of cancer: the next generation,” Cell, Mar. 4, 2011, 144(5):646-74. [cited by applicant]
Heasman, “Morpholino oligos: making sense of antisense?,” Developmental Biology, Mar. 15, 2002, 243(2):209-14. [cited by applicant]
Herzog et al., “Impact of molecular profiling on overall survival of patients with advanced ovarian cancer,” Oncotarget, Apr. 12, 2016, 7(15):19840-9. [cited by applicant]
Hicke et al., “Escort aptamers: a delivery service for diagnosis and therapy,” The Journal of Clinical Investigation, Oct. 15, 2000, 106(8):923-8. [cited by applicant]
Higuchi et al., “Production of single-stranded DNA templates by exonuclease digestion following the polymerase chain reaction,” Nucleic Acids Research, Jul. 25, 1989, 17(14):5865, 1 Page. [cited by applicant]
Hirose et al. “Rapid synthesis of trideoxyribonucleotide blocks,” Tetrahedron Letters, Jan. 1, 1978, 19(28):2449-52. [cited by applicant]
Hobbs et al., “Polynucleotides containing 2′-amino-2′-deoxyribose and 2′-azido-2′-deoxyribose,” Biochemistry, Dec. 1, 1973, 12(25):5138-45. [cited by applicant]
Hofacker et al., “Fast folding and comparison of RNA secondary structures,” Monatshefte für Chemie/Chemical Monthly, Feb. 1, 1994, 125(2):167-88. [cited by applicant]
Hofacker, “Vienna RNA secondary structure server,” Nucleic Acids Research, Jul. 1, 2003,31(13):3429-31. [cited by applicant]
Hoopmann et al., “Tumor M2 pyruvate kinase-determination in breast cancer patients receiving trastuzumab therapy,” Cancer Letters, Dec. 10, 2002, 187(1-2):223-8. [cited by applicant]
Horton, “Trastuzumab use in breast cancer: clinical issues,” Cancer Control, Nov. 2002, 9(6):499-507. [cited by applicant]
Hurley et al., “Membrane budding and scission by the ESCRT machinery: it's all in the neck,” Nature Reviews Molecular Cell Biology, Aug. 2010 Aug. 11(8):556-566. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2017/23108, dated Sep. 18, 2018, 7 pages. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2017/34567, dated Nov. 27, 2018, 7 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2017/23108, mailed on Jul. 7, 2017, 11 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2017/34567, mailed on Aug. 25, 2017, 11 pages. [cited by applicant]
Ithimakin et al., “HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab,” Cancer Research, Mar. 1, 2013, 73(5):1635-46. [cited by applicant]
Jain, “Integrative omics, pharmacoproteomics, and human body fluids,” Proteomics of Human Body Fluids, Humana Press, 2007, 175-192. [cited by applicant]